The liver is the most common site of metastasis of neuroendocrine tumors (NETs). Gastroenteropancreatic (GEP)-NETs are rare, and the distinction between hepatocellular carcinoma (HCC) and metastatic NET can be difficult due to the similarity of their histological characteristics. Herein, we report a case of GEP-NET with hepatic metastasis, which was first misdiagnosed as HCC by liver biopsy and subsequently re-diagnosed after surgery as primary GEP-NET. (Korean J Med 2019;94:449-454) 
INTRODUCTION
Neuroendocrine tumors (NETs) originate from heterogenous neuroendocrine cells of various organs, such as the pancreas, gastrointestinal tract, and lung, as well as the parathyroid, adrenal, and pituitary glands or parafollicular C cells of the thyroid gland.
The overall annual age-adjusted incidence of NETs is 6.98/ 100,000 in the United States, according to the surveillance, epidemiology, and end results (SEER) registry. The incidence of NET is 3.56/100,000 persons, affecting a variety of gastroenteropancreatic (GEP) sites (including 1.05/100,000 persons with small-intestinal NET, 1.04/100,000 persons with rectal NET, and 0.48/100,000 persons with pancreatic NET) [1] . In the Asian population, the incidence of NET was reportedly 2.2/100,000 in 2004, and the proportion of NETs with a GEP origin was 58.2% in the rectum, 11.4% in the pancreas, 9.5% in the stomach, 5.6% in the duodenum, 5.6% in the jejunum/ileum, 7.0% in the colon, and 2.8% in the appendix [2] . In a multicenter study of GEP-NET in South Korea, the annual incidence of GEP-NET was found to have increased significantly from 2000 and 2009, and the rates of NET in specific organs differed compared to previous Western reports (48.0% in the rectum, 14.6% in the stomach, 8.7% in the pancreas, 7.7% in the small intestine, 7.9% in the colon, and 2.5% in the appendix) [3] .
Fewer NETs originate from the small intestine than from other organs, and such NETs typically show an indolent clinical course.
The nonspecific clinical symptoms often delay the diagnosis of NETs, and distant metastases are commonly detected at the time of initial diagnosis.
The liver is the most common site of GEP-NET metastases, and hepatic metastases are the most powerful predictor of survival in patients with GEP-NET. However, distinguishing between hepatocellular carcinoma (HCC) and NET metastases to the liver can be challenging, depending on the biopsy size, as some metastatic NETs may have similar cytological characteristics, such as increased cytoplasm, presence of nucleoli, and lack of salt-and-pepper chromatin, which may cause confusion with HCC [4, 5] . Here, we report a case of GEP-NET with hepatic metastasis, which was first misdiagnosed as HCC by liver biopsy but was re-diagnosed after surgery as primary GEP-NET.
CASE REPORT
A 73-year-old man visited a local clinic due to discomfort in both hands and legs. The findings of initial spine magnetic resonance imaging (MRI) were normal, but the results of initial laboratory tests showed hypokalemia, and the patient had a history of hypertension. Thus, he was referred to a specialist for a hyperaldosteronism workup and was diagnosed with hyperaldosteronism due to detection of a left adrenal mass by abdominal computed tomography (CT), which also detected multiple hepatic masses. The patient had no definite history of hepatitis B or C, and he was negative for other hepatitis markers, except for HBcAb, and the level of the tumor marker alpha-fetoprotein (AFP) was within the normal range (1.82 ng/mL). Thus, the patient underwent liver biopsy at a local hospital, resulting in a diagnosis of HCC. The patient wished to have his HCC treated in a more advanced hospital; thus, he was referred to Kangbuk Samsung Hospital.
We attempted to re-biopsy the hepatic mass on hepatic segment 4 for accurate diagnosis despite the diagnosis of HCC of Edmondson-Steiner grade 2 (Fig. 1) . The HCC was classified as Therefore, the tumor cells in the liver were presumed to be metastases of large cells from intestinal NETs (Fig. 4) .
These results were confusing as the resected hepatic nodule was first diagnosed as HCC by liver imaging. We thus reviewed the previous imaging and pathological findings to ensure that the hepatic mass was first diagnosed as HCC. After discussion with a pathologist and repeat immunohistochemical staining of the first biopsy specimen, we found that the first biopsied hepatic mass was actually a NET, not HCC ( Fig. 5 ). Because the first pathological analyses were suggestive of HCC and the patient had a history of positivity for HBcAb, no further immunohistochemical staining for NET was performed and the hepatic mass was initially diagnosed as HCC.
We assessed the levels of other markers of NET, such as The effectiveness of surgical interventions is a matter of debate, although two studies have reported that surgery is effective for primary GEP-NET with distant metastases [9, 10] . In our case, because the patient had an elevated serum concentration of 5-HIAA, systemic therapy with a somatostatin analog or chemotherapy after removal of the primary GEP-NET was considered.
In summary, we present a case of GEP-NET with hepatic metastasis that was first misdiagnosed as HCC by liver biopsy, and later re-diagnosed as NET by immunochemical staining. It is important to be aware that a hepatic mass can be a primary hepatic carcinoma or a metastatic lesion originating at an extrahepatic site. If any biopsy or imaging result is suggestive of NET, measurements of the levels of tumor biomarkers in blood, as well as immunochemical staining, must be performed. Accurate diagnosis and appropriate treatment depend on a multidisciplinary assessment with close cooperation among physicians, surgeons, radiologists, and pathologists.
중심 단어: 신경내분비종양; 간세포암; 진단오류
